S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:NEO

NeoGenomics (NEO) Stock Forecast, Price & News

$9.74
+1.47 (+17.78%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$8.41
$9.84
50-Day Range
$7.38
$18.97
52-Week Range
$7.26
$54.74
Volume
3.41 million shs
Average Volume
1.96 million shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86
30 days | 90 days | 365 days | Advanced Chart
Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NeoGenomics logo

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Headlines

StockNews.com Upgrades NeoGenomics (NASDAQ:NEO) to "Sell"
NeoGenomics (NASDAQ:NEO) Reaches New 52-Week Low at $9.13
See More Headlines

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.19 per share
Book Value
$8.62 per share

Profitability

Net Income
$-8.35 million
Pretax Margin
-9.69%

Debt

Price-To-Earnings

Miscellaneous

Free Float
123,510,000
Market Cap
$1.22 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/16/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.48 out of 5 stars

Medical Sector

156th out of 1,403 stocks

Testing Laboratories Industry

1st out of 1 stocks

Analyst Opinion: 4.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view top-rated stocks.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for NeoGenomics
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Wednesday, April, 27th. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. The medical research company had revenue of $117.17 million for the quarter, compared to analysts' expectations of $116.44 million. NeoGenomics had a negative trailing twelve-month return on equity of 6.62% and a negative net margin of 7.33%. NeoGenomics's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the company posted ($0.06) earnings per share.
View NeoGenomics' earnings history
.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its first quarter 2022 earnings guidance on Monday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of -$118 million, compared to the consensus revenue estimate of $119.16 million.

What price target have analysts set for NEO?

10 brokers have issued 12-month price objectives for NeoGenomics' stock. Their forecasts range from $16.00 to $55.00. On average, they anticipate NeoGenomics' share price to reach $24.64 in the next year. This suggests a possible upside of 152.9% from the stock's current price.
View analysts' price targets for NeoGenomics
or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?
NeoGenomics' management team includes the following people:
  • Ms. Lynn A. Tetrault Esq., J.D., Exec. Chairman & Principal Exec. Officer (Age 59, Pay $97.67k)
  • Ms. Halley E. Gilbert Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 52, Pay $445.38k)
  • Mr. George A. Cardoza, Pres & COO of Lab Operations (Age 60, Pay $800.5k) (LinkedIn Profile)
  • Ms. Kathryn B. McKenzie, Chief Sustainability & Risk Officer (Age 38, Pay $793.48k) (LinkedIn Profile)
  • Prof. Clive D. Morris M.B.A., M.D., Pres at Inivata (Age 51, Pay $940.31k)
  • Mr. William Bishop Bonello, Chief Financial Officer (Age 57)
  • Ms. Cynthia J. Dieter, Chief Accounting Officer (Age 47)
  • Mr. John Mooney, Chief Technology Officer
  • Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D., Exec. VP of R&D and Chief Scientific Officer
  • Charlie Eidson, Director of Investor Relations and Corp. Devel.
What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.40%), Brown Advisory Inc. (3.69%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.13%), Emerald Advisers LLC (0.88%) and Emerald Mutual Fund Advisers Trust (0.77%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Eagle Asset Management Inc., Verition Fund Management LLC, Granite Investment Partners LLC, American Century Companies Inc., Dimensional Fund Advisors LP, SG Americas Securities LLC, and King Luther Capital Management Corp. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Robert J Shovlin, and William Bonello.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was purchased by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Royce & Associates LP, Citigroup Inc., Renaissance Technologies LLC, Emerald Advisers LLC, Cowen Prime Advisors LLC, Duality Advisers LP, and Vanguard Group Inc..
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $9.74.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $1.22 billion and generates $484.33 million in revenue each year. The medical research company earns $-8.35 million in net income (profit) each year or ($0.320010) on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 2,000 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.